A Review on Drug Molecules Targeting to Brain

Keywords

Blood-brain barrier, Drugs, Central nervous system

Introduction

The advancement of new drugs for the mind has not kept pace with advancement in the molecules neurosciences, in light of the fact that the larger part of new drugs found don't cross the blood-brain barrier (BBB) [1]. Now a day target delivery of drug molecules to brain is one of the most exacting researches filed in pharmaceutical sciences [2,3]. The blood-brain barrier (BBB) represents an impediment for a huge number of drugs, including antibiotics, antineoplastic agents [4-6], and a variety of central nervous system (CNS)-active drugs, especially neuropeptides. Therefore, different scenarios have been proposed to increase the outcome of various drugs to this tissue which adds colloidal drug carriers, liposomes, nanoparticles and olfactory route of administration and nano-technology [7-10]. This review deals in short about the status of the BBB, distinctive pathologies of cerebrum like neurodegenerative, cerebrovascular and inflammatory diseases. The primary piece of this subject expects to audit the significance of BBB and convey drugs into the brain. The use of nano-technology and liposomes as mainly used to target various CNS disorders. The later part of this topic contains future aspects of brain drug targeting and some patents of drugs [11-12].

Importance of Brain Targeting System

• The worldwide business sector for medications for the central nervous system (CNS) isextraordinarily immature and would need to develop by more than 500% fair to be equivalent tothe worldwide business sector for cardiovascular drugs [13,14]. The guideline purpose behindthis being worked on of the worldwide brain drug business is that the immense greater part ofdrugs doesn’t cross the brain narrow divider, which frames the blood-brain barrier (BBB) in vivo.

• The blood-brain barrier (BBB) represents an impediment for a huge number of drugs, includingantibiotics, antineoplastic agents, and a variety of central nervous system (CNS)-active drugs,especially neuropeptides. Blood-Brain Barrier is located at the level of brain capillaries, wherethere is a concurrence of various cell types; Oligodendroglia, pericytes, astrocytes and microglias[15-20].

• The brain micro vessel endothelial cell (BMEC) that form the blood-brain barrier, show essentialmorphological attributes, for example, the vicinity of tight intersections between the cells [21-23],the nonappearance of fenestrations and a decreased pinocytics action, that together help to limitthe entry of mixes from the blood into the additional cell environment of the brain [24,25].

• Each slender vessel is bound by a solitary layer of endothelial cells, associated by tightintersection, subsequently making it extremely troublesome for most molecules to leave thevessels and penetrate into the brain. Tight intersections give huge transendothelial electricalresistance (TEER) to BMEC and obstruct the entrance of potential restorative operators suchasoligonucleosides, antibodies, peptides and proteins. Besides, BMEC express a mixed bag ofcatalysts, both cytosolic and on the additional cell film which additionally add to the prohibitiveway of the BBB.

• P-glycoprotein (P-gp) is also present in the luminal plasma membrane of BMEC [26-28].

Brain Disorders

Meningitis

Meningitis is an inflammation of the meninges. The meninges are the slender layers of tissue that cover the brain and the spinal cord. Meningitis is most ordinarily genesis about by infection (by bacteria, viruses, or fungi). It can likewise be created by draining into the meninges, malignancy, infections of the resistant systems, and different factors. The most unsafe types of meningitis are those brought about by bacteria. The disease is intense and can be lethal [29-31].

Encephalitis

Encephalitis implies an inflammation of the cerebrum. This inflammation of the brain brought on by the viral and bacterial disease. Both the brain and spinal cord are included, encephalomyelitis issue. Encephalitis ranges from gentle to extreme which may bring about changeless neurological harm and death.

Encephalitis is an uncommon illness. It happens in more or less 0.5 every 100,000 people. It is most normal among in kids and individuals with debilitated immune systems. A few individuals who have encephalitis are left with unceasing brain damage [32-37].

Anatomy of Blood Brain Barrier

An anatomic-physiologic highlight of the brain thought to comprise of walls of vessels in the focal sensory system and encompassing astrocytic glial layers.

The boundary isolates the parenchyma of the focal sensory system from blood (Figure 1). The blood brain barrier anticipates or moderates the entry of a few drugs and other substance mixes, radioactive particles, and infection creating organic entities, for example, infections from the blood into the central nervous system [38-42].

Figure 1: a. schematic diagram of Blood Brain Barrier, b. The brain and nearby structures, c. Major parts of the brain

Importance of the Barriers

• Blood Brain Barrier

• Blood-Cerebrospinal Fluid Barrier

• The Nose-Brain barrier

• Arachnoid matter cerebrospinal fluid barrier

Without the BBB, undesirable molecules could unreservedly diffuse from the vessels to the liquid that encompasses the brain cells

• These undesirable molecules include:

Toxins: Substances created by plants and animals that are poisonous to humans [43].

Ions: Atoms with extra electrons or missing electrons.

Acids and Bases: Common solutions that exist everywhere, almost every liquid that we encounter in our daily lives consists of acidic and basic properties, with the exception of water. They have completely different properties and are able to neutralize to form H2O, which will be discussed later in a subsection [44-46].

• The BBB also incorporates mechanisms to transport certain substances in:

Glucose: The universal energy source, which is needed by every cell in your body.

Oxygen: Electron acceptor par excellence, do without it and die.

Certain Ions: Cations, Anions, Chlorine, Calcium, etc. Involved in nervous system transmission [47].

• The BBB also lets various substances in because it either can't pump them out or itsmechanisms can't tell the difference between them and one of the substances that it naturallytranports across: Ethanol- enters by the same pathways that let glucose in, which is why drinking alcohol affectsthe brain. Vitamin C, Nicotine, Caffeine [48,49].

Multiple Functions of Blood Brain Barrier

1) Function as an active pump:

Binding of a substrate and ATP molecule happen at the same time. Taking subsequent to tying, ATP hydrolysis moves the substrate into a position to be discharged from the cell. Arrival of the phosphate (from the first ATP atom) happens simultaneously with substrate discharge. ADP is discharged, and another particle of ATP ties to the optional ATP-tying site. Hydrolysis and arrival of ADP and a phosphate molecule resets the protein [50-52].

2) Function as metabolite barrier:

5-HTP promptly crosses the blood-brain barrier and moreover is quickly decarboxylated to serotonin (5-hydroxytryptamine or 5-HT) and hence may be valuable for the treatment of wretchedness. Howeverserotonin has a moderately short half-life since it is quickly metabolized by monoamine oxidase, andhence is liable to have restricted adequacy.

3) Rate-limiting role of the BBB in brain drug development:

Present-day incongruities in brin drug advancement are shown by a thought of a portion of the attributes of the CNS drug industry. Though 98% of all little atom medications don't cross the BBB, and about 100% of large-molecule drugs don't cross the BBB, with a few studies having co infused Polysorbate 80, a cleanser that can disturb the BBB, with the drug as a balancing out specialists, and erroneously ascribing the cleanser impacts to their own particular nanoparticles. In different studies, the large size of the liposomes that were used produced micro embolism that gave a bogus impression of brain uptake [53-64].

Drug Transport through Blood Brain Barrier

• Carrier-mediated transport can likewise be partitioned into various distinctive instrumentssubject to vitality and/ or co-transport of another substance. Co-transport may be in the samebearing (symport) or the other way (antiport). This procedure continues from a district of highfixation to an area of low focus.

• Endocytosis can be isolated into bulk-phase, otherwise called fluid phase endocytosis andintervened endocytosis (receptor and absorptive interceded).

• Bulk-phase endocytosis (pinocytosis) is the nonspecific uptake of extracellular liquids andhappens at a constitutive level inside of the cell by means of systems, which are autonomous ofligand tying. Bulk-phase endocytosis is temperature and vitality subordinate, non-focused, andnon-saturable. Bulk-phase endocytosis strikes an extremely restricted degree in the endothelialcells of the cerebral microvasculature [65-69].

• Receptor-intervened endocytosis (RME) gives an intends to particular uptake of macromolecules.Cells have receptors for the uptake of a wide range of sorts of ligands, including hormones,development variables, compounds, and plasma proteins. RME happens at the brain forsubstances, for example, transferrin, insulin, leptin and IGF-I & IGF and is a profoundly particularsort of vitality ward transport.

• Absorptive-interceded transport (AME) is activated by an electrostatic connection between anemphatically charged substance, as a rule a charge moiety of a peptide, the contrarily chargeplasma membrane surface (i.e. glycocalyx). AME has a lower fondness and higher limit thanreceptor-intervened endocytosis [70-76].

Factors Affecting Drug Permeation through Blood Brain Barrier

Drug absorption depends on the lipid solubility of the drug, its formulation and the route of administration.

• A drug needs to be lipid solvent to infiltrate membranes unless there is a dynamic transportsystem or it is small to the point that it can go through the fluid diverts in the membrane.

• Traditional oral or parenteral organization may not accomplish ideal restorative concentrations ofdrug at its site of activity. After oral organization, metabolism system of the drug in the gut or livermay bring about low systemic bioavailability. Modern technology has created conveyancesystems that permit exact control of drug data into the body by more unorthodox routes.

Strategies of Brain Drug Delivery System

• The blood- Brain Barrier (BBB) remains a noteworthy obstruction to the effective conveyance ofdrug to treat central nervous system (CNS) issue. Specialists are investigating an assortment ofways to deal with protect the capacity of the BBB to square unsafe and poisonous substancesfrom entering the brian and to allow the section of viable pharmaceuticals for the treatment ofCNS. "The key test is to treat individuals experiencing CNS issue while attempting to stayconsistent with the doctor's oath,'Firstdonoharm'." [77]

• One innovation for empowering dynamic transport of little atom medicates over the BBB includesfocusing on endogenous supplement transporters. These transporters are individuals from thesolute carrier (SLC) transporter super gang. Transport of little particles over the BBB by theselayer proteins is known as transporter mediated transport (CMT) [78-80].

• Another major system that is utilized as a part of typical mammalian physiology to empowerrequired molecules to cross the BBB is receptor- mediated transport (RMT). The brain utilizesRMT to transport proteins, peptides, and lipoproteins that are required for brain work over theBBB. Examples of biomolecules that are transported into the cerebrum by means of RMTincorporate insulin, insulin-like growth factor (IGF), leptin, transferrin, and low-density lipoprotein(LDL) [81-84].

Methods for Brain Delivery Strategies

Several drugs don't have satisfactory physiochemical qualities, for example, high lipid dissolvability, low molecular size and positive charges which are vital to succeed in crossing BBB

1) Neurosurgical/Invasive strategies:

• Disruption of the BBB: -

The idea behind this methodology was to separate the obstruction quickly by infusing mannitolarrangement into courses in the neck. The subsequent high sugar fixation in brain capillaries takesup water out of the endothelial cells, contracting them in this way opening tight intersection [85-87]. The impact goes on for 20-30 minute, amid which time drugs diffuse uninhibitedly, that wouldnot typically cross the BBB. This technique allowed the conveyance of chemotherapeutic agents inpatients with cerebral lymphoma, threatening glioma and spread CNS germ cell tumors [88-89].

• Intraventricular / Intrathecaldelivery: -

Here utilizing a plastic repository which embedded subcutaneously in the scalp and associated withthe ventricles inside of the brain by an outlet catheter. Drug injection into the CSF is a suitabletechnique for destinations near to the ventricles only.

• Intra Nasal Drug Delivery: -

At the point when a nasal drug plan is conveyed profound and sufficiently high into the nasal cavity,the olfactory mucosa may be come to and drug transport into the brain and/or CSF by means ofthe olfactory receptor neurons may occur.

2) Pharmacological Based Strategies:

• Colloidal Drug Carriers:-

Colloidal drug carrier systems, for example, micellar arrangements, vesicle and liquid crystal dispersions, and nanoparticle scatterings comprising of little particles of 10- 400 nm width show incredible guarantee as drug delivery systems. The objective is to acquire systems with improved drug stacking and discharge properties, long time span of usability and low poisonous quality. The incorporated drug takes part in the microstructure of the system, and may even impact it because of molecular associations, particularly if the medication forces amphiphillic and/or mesogenic properties [90-93].

Pharmaceutical Carriers

Micelles

Micelles formed by self-assembly of amphiphilic block copolymers (5-50 nm) in watery arrangements are of great enthusiasm for drug conveyance applications (Figure 2). The drugs can be physically captured in the center of block copolymer micelles and transported at fixations that can surpass their natural water- solvency [94-96]. Besides, the hydrophilic blocks can shape hydrogen bonds with the fluid surroundings and structure a tight shell around the micellar core. Subsequently, the substance of the hydrophobic core is adequately secured against hydrolysis and enzymatic debasement. Functionalization of block copolymers with cross linkable groups can expand the dependability of the relating micelles and enhance their temporal control [97-99].

Figure 2: Types of Pharmaceutical Carriers

Block Copolymer Micelles

Liposomes

In Liposomes, one end of every molecule is water solvent, while the inverse end is water insoluble. Water-dissolvable medicines added to the water were caught inside the conglomeration of the hydrophobic closures; fat-solvent pharmaceuticals were joined into the phospholipid layer [100] (Figure 3).

Figure 3: Liposomes, Micelles, Bilayer sheet

Nanotechnology

Nanoparticulate Systems for Brain Delivery of Drugs

Nanoparticles are polymeric particles made of regular or simulated polymers going in size between around 10 and 1000 nm (1 mm). Drugs may be bound inform of a solid solution or scattering or be adsorbed to the surface or chemically attached.

Ex: Poly (butyl cyano acrylate) nanoparticles represent the only nanoparticles that were so far successfully used for the in vivo delivery of drugs to the brain. The first drug that was de-livered to the brain using nanoparticles was the hexapeptidedalargin (Tyr-D-Ala- Gly- Phe-Leu-Arg), a Leu-enkephalin analogue with opioid activity [101-104].

The nanotechnology includes;-

➢ Coated nanoparticles

➢ Pegylated nanoparticles

➢ Solid Lipid nanoparticles (SLN)

➢ Nanogels

Advantages of Nanotechnology

• Due to their little size nanoparticles enter into even small capillaries and are taken up inside of cells, permitting an effective drug aggregation at the focused on locales in the body [105].

• The utilization of biodegradable materials for nanoparticle preparation, permits maintainedmedication discharge at the focused in the vicinity after injection more than a time of days or evenweeks [106].

Physiologic Based Strategies

• Chimeric Peptide Technology

Chimeric peptides are framed when a drug that is typically not transported through the BBB, is conjugated to a drug-targeting vector. The recent is an endogenous peptide, modified protein, or peptidomimetic monoclonal antibody (mab) that experiences RMT (Rapid metabolic transfer) through the BBB on endogenous receptor systems, for example, the insulin receptor. Peptidomimetic mabs tie to exofacial epitopes on the BBB receptor that are expelled from the endogenous ligand tying site and cross the BBB on the endogenous RMT system inside of the BBB [107].

Ex: Brain drug delivery in rats is possible with the OX26 mouse mab to the rat tfr. Brain drug delivery in humans is possible with the genetically engineered chimeric HIR mab.

• Neuroprotection with Peptide Radiopharmaceuticals

The brain imaging practice utilizes small-molecule radio chemicals that tie to monoamine or amino corrosive neurotransmitter systems. Though there are less than a dozen monoaminergic or aminoacidergic neurotransmitter systems, there are several peptidergic neurotransmission systems. Thusly, the utilization of peptide radiopharmaceuticals could incredibly build the analytic capability of neuro imaging technology [108-111].

Ex: Potential candidates for neuro imaging include epidermal growth factor (EGF) peptide radiopharmaceuticals for the early detection of brain tumors and peptide radiopharmaceuticals as a diagnostic brain scan for Alzheimer disease.

• Protein Neurotherapeutic Agent and Neuroprotection In Stroke

All small-molecule neuroprotective agents have fizzled in clinical stroke trials in light of the fact that either (a) these molecules have unfavorable security profiles or (b) the drugs don't cross the BBB.

The restorative window for neuroprotection is the initial 3 hours after stroke, and amid this time, the BBB is in place. The BBB is upset in later stages taking after stroke, however right now, chances for neuroprotection have been lost. Along these lines, if powerful neuroprotective specialists for stroke are to be created, these molecules must have great wellbeing profiles and must have the capacity to cross the BBB [112-114].

Ex: A model neurotrophin, brain-derived neurotrophic factor (BDNF), was reformulated to enable BBB transport, and the BDNF chimeric peptide is neuroprotective following delayed intravenous administration.

Future Prospects of Brain Drug Delivery

There are many technological challenges to be met, in developing the following techniques:

• Materials for nanoparticles those are biocompatible and biodegradable.

• Devices for recognizing changes in attractive or physical properties after particular tying of ligandson paramagnetic nanoparticles that can connect with the measure of ligand [115-116].

• Infection like systems for intracellular conveyance.

• Nanoparticles to enhance devices, for example, implantable devices /nanochips for nanoparticledischarge, or multi supply medicate conveyance chips

• Nano - drug conveyance systems that convey huge however exceedingly confined quantities ofdrugs to particular regions to be discharged in controlled ways

• Controllable release profiles, particularly for sensitive drugs

• Nanoparticles for tissue engineering; e.g. for the conveyance of cytokines to control cellular growthand separation, and stimulate recovery; or for covering implants with nanoparticles inbiodegradable polymer layers for supported release.

• Easy to understand lab-on-a-chip devices for purpose of-consideration and disease prevention andcontrol at home.

• Architectures/ structures, for example, biomimetic polymer, nanotubes.

• Progressed polymeric carriers for the conveyance of therapeutic peptide/proteins(biopharmaceutics), And additionally in the improvement of: Combined treatment and medicalimaging, for instance, nanoparticles for determination and control amid surgery (e.g.Thermotherapy with attractive particles). Cell and gene targeting systems.

Recent patents

Conclusion

Brain Targeting has got the consideration of the numerous analysts because of its application in different diseases identified with CNS. Just few drugs can infiltrate the BBB and enters the CNS, so different systems are created for drug conveyance. It rises that the nanotechnology and by utilizing different courses of drug administration like intra nasal procedure drug can infiltrate the BBB proficiently. Further the altered colloidal particles and different adjusted liposomes upgrade presentation of the BBB because of delayed blood dissemination, which supports cooperation and entrance into brain endothelial cells. This system has clinical advantages like lessened drug measurement, diminished symptoms, non invasive routes, and more patient compliance. We still require developing a cost effective system that can be used in various CNS disorders efficiently with minimum side effect.

References

1. Cramer S et al. The Influence of Silver Nanoparticles on the Blood-Brain and the Blood-CerebrospinalFluid Barrier in vitro. J Nanomed Nanotechnol 2014; 5:225.
2. Arturas Ziemys et al. Transport model for drug release from delivery vectors accounting for chemical andmicrostructure properties. Pharmaceut Anal Acta 2013; 4:2.
3. Tamilselvan N et al. Targeted delivery of Rivastigmine loaded PLGA nanoparticles into the brain fortreating Alzheimer’s disease. Pharmaceut Anal Acta 2013; 4:2.
4. Barik BB. Drug Delivery System “A Challenge” for New Therapeutic Era. Pharm Anal Acta 2015; 6:1.
5. D’Alessandris QG et al. Prognostic Impact of MGMT Promoter Methylation in Glioblastoma - A SystematicReview. J Cancer Sci Ther 2014; 6:136-141.
6. Cham BE. Drug therapy: Solamargine and other solasodine rhamnosyl glycosides as anticancer agents. JCancer Sci Ther 2013; 5:10.
7. Gulua L et al. Development of technology of production of plant nanocomposites and study of theirbioactivity. J Nutr Food Sci 2012; 2:7.
8. Waszkielewicz AM. Short Commentary on Current Trends in Medicinal Chemistry of the Central NervousSystem. Organic Chem Curr Res 2014; 3:e135.
9. Changal KH and Raina AH. Central Nervous System Manifestations of Tuberculosis: A Review Article. JMycobac Dis 2014; 4:146.
10. Chen L et al. Effect of Adjuvant Radiotherapy in the Management of Hemangiopericytoma of the CentralNervous System:Report of 5 Cases. J Nucl Med Radiat Ther 2014; 5:184.
11. Elizabeth C M de Lange. The mastermind research approach for prediction of human CNS drug effects:“Right place, right time, right concentration” in health and disease. Clinic Pharmacol Biopharm 2014;3:2.
12. Sani M et al. Successful Regeneration of CNS Nerve Cells a Possible Bye Bye O Debilitating Effects OfNeurodegenerative Diseases. J Alzheimers Dis Parkinsonism 2015; 5:182.
13. Fredy IC et al. Cardiovascular Medicine Safety Profile Evaluation among Urban Private Hospitals. AdvPharmacoepidemiol Drug Saf 2015; 4:175.
14. Sangeeta Tanna and Graham Lawson. Cardiovascular drug medication compliance assessed by driedblood spot sampling techniques. J Anal Bioanal Tech 2013; 4:5.
15. Surajit S. Protein Aggregation in Neurodegenerative Disorders: A Cause or Consequence? Adv Tech BiolMed 2014; 2:e105.
16. Sara Ahmadi. Development of novel targeted drug delivery systems for the treatment of epilepsy. PharmAnal Acta 2015; 6:1.
17. Luisa Fiandra et al. Delivery of nanoformulated antiretroviral drugs across the blood brain barrier. PharmAnal Acta 2015; 6:1.
18. G Yurtdas Kirimlioglu et al. Gaba containing polymeric nanoparticulate system for brain delivery. JNanomed Nanotechnol 2014; 5:5.
19. Amanda M Brown. Human immunodeficiency virus type i neuropathogenesis in the age of combinedantiretroviral therapy: The role of inflammation. J Antivir Antiretrovir 2014; 6:2.
20. Wael Alata et al. Cerebral glucose transport and blood-brain barrier morphology are altered in function ofapolipoprotein E genotype in mice. J Alzheimers Dis Parkinsonism 2014; 4:5.
21. Munikumar M et al. In Silico Identification of Common Putative Drug Targets among the Pathogens ofBacterial Meningitis. Biochem Anal Biochem 2012;Pier Giovanni Baraldi et al. New agonists of the CB2 cannabinoid receptor: Discovery of a new class ofanalgesic compounds. Med Chem 2014; 4:12.
22. Munikumar M et al. In Silico Identification of Common Putative Drug Targets among the Pathogens ofBacterial Meningitis. Biochem Anal Biochem 2012;Ian Tizard and Susan L Payne. A Unique virus-mediated neurologic disease causing intestinal paralysis inbirds. J Antivir Antiretrovir 2014; 6:2.
23. Munikumar M et al. In Silico Identification of Common Putative Drug Targets among the Pathogens ofBacterial Meningitis. Biochem Anal Biochem 2012;Atroshi Faik et al. Diet and nutrition in disease management. J Pharmacogenomics Pharmacoproteomics2014; 5:5.
24. Munikumar M et al. In Silico Identification of Common Putative Drug Targets among the Pathogens ofBacterial Meningitis. Biochem Anal Biochem 2012;Chun-Yuan Shih-Huang and Yung-ChihKuo. Solid lipid nanoparticles carrying chemotherapeutic drugacross the blood-brain barrier through insulin receptor-mediated pathway. J Tissue Sci Eng 2013; 4:2.
25. Munikumar M et al. In Silico Identification of Common Putative Drug Targets among the Pathogens ofBacterial Meningitis. Biochem Anal Biochem 2012;Maria Alexandra Brito et al. Blood-brain barrier disruption by neurotoxins. J Clinic Toxicol 2012; 2:9.
26. Munikumar M et al. In Silico Identification of Common Putative Drug Targets among the Pathogens ofBacterial Meningitis. Biochem Anal Biochem 2012;Fortuna A et al. In vitro and In vivo Relevance of the P-glycoprotein Probe Substrates in Drug Discoveryand Development: Focus on Rhodamine 123, Digoxin and Talinolol. J Bioequiv Availab 2011; S2.
27. Munikumar M et al. In Silico Identification of Common Putative Drug Targets among the Pathogens ofBacterial Meningitis. Biochem Anal Biochem 2012;Neerati P et al. Curcumin Regulates Colon Cancer by Inhibiting P-Glycoprotein in In-situ Cancerous ColonPerfusion Rat Model. J Cancer Sci Ther 2013; 5:313-319.
28. Munikumar M et al. In Silico Identification of Common Putative Drug Targets among the Pathogens ofBacterial Meningitis. Biochem Anal Biochem 2012;Muhammad Delwar Hussain Targeted drug delivery in cancer with multifunctional nanoparticles.Pharmaceut Anal Acta 2014; 5:3.
29. Munikumar M et al. In Silico Identification of Common Putative Drug Targets among the Pathogens ofBacterial Meningitis. Biochem Anal Biochem 2012; 2:123.
30. Gudza-Mugabe M et al. Bacterial Paediatric Meningitis Laboratory Diagnosis. J Cell Sci Ther 2015; 6:204.
31. Radouani MA et al. Epidemiological Study of Neonatal Bacterial Meningitis: Moroccan Data. J Infect DisTher 2014; 2:167.
32. Saxena SK et al. Current Scenario of Antiviral Drugs for Japanese Encephalitis. J Med Microb Diagn2014; 3:133.
33. Pedraza-Ordoñez F et al. The Use of Real-Time PCR (qPCR) for the Diagnosis of Bovine Herpes virus 5 inFormalin-Fixed, Paraffin-Embedded Bovine Brain Samples Identified as Bovine Unspecific Encephalitis. JVeterinar Sci Technol 2013; 4:145.
34. Kevin B Spurgers and Pamela J Glass. Vaccine Development for Biothreat Alphaviruses. J Bioterr Biodef2011; S1:001.
35. Konishi E and Takizawa Y. Effect of Pre-Existing Immunity to Flaviviruses on Balanced Induction ofNeutralizing Antibodies by a Dengue Tetravalent DNA Vaccine in Mice. J Vaccines Vaccin 2010; 1:102.
36. Bröker M et al. Genetic Stability of a Tick-Borne Encephalitis (TBE) Virus Strain used for the Production ofa TBE Vaccine. J Vaccines Vaccin 2011; 2:114.
37. Kataoka H et al. Four-Year Course of Serum and Cerebrospinal Fluid Antibody Titers in a Patient with Anti-NMDAR Encephalitis. J Genet Syndr Gene Ther 2014; 5:221.
38. Arias VM et al. Neurological Deterioration in a PML-HIV Patient in the Absence of Immune ReconstitutionInflammatory Syndrome. J Mult Scler 2014; 1:125.
39. Briones BA et al. Adenosine’s Autacoid Function in the Central Nervous System and the Behavioral Stateof Conservation-Withdrawal. Autacoids 2014; 3:106.
40. Kuo-Chi Hung and Hsi-Kung Kuo. Unilateral Optic Nerve Leukemic Infiltration and Exudative RetinalDetachment as Initial Manifestations of Central Nervous System Relapse in Acute LymphoblasticLeukemia of Children. J Clin Exp Ophthalmol 2014; 5:359.
41. Christopher R Showers et al. Immunopathology of Central Nervous System Tumors. Immunome Res2014; 10:077.
42. Chen L et al. Effect of Adjuvant Radiotherapy in the Management of Hemangiopericytoma of the CentralNervous System:Report of 5 Cases. J Nucl Med Radiat Ther 2014; 5:184.
43. Vahabzadeh M and Mohammadpour HA. Effect of Diabetes Mellitus on the Metabolism of Drugs andToxins. J Clin Toxicol 2015; 5: 233.
44. Pankaj Kumar Arora. Toxicity and degradation of chlorinated nitroaromatic compounds. J BioequivAvailab 2012; 4.3.
45. Abhishek Kumar Jain. The novel modified approaches for enhancement of bioavailability of poorlywatersoluble drugs. J Bioequiv Availab 2012; 4.3.
46. Stächele J et al. Toxic Optic Neuritis due to Isotretinoin in a Child with Neuroblastoma: A Case Report. JClin Toxicol 2015; 5:241.
47. Gong ZY et al. A Ringdown Breath Acetone Analyzer: Performance and Validation Using GasChromatography-Mass Spectrometry. J Anal Bioanal Tech 2014; S7:013.
48. Lindholm H et al. The FDG-Uptake of Adipose Tissue is Higher in Individuals with Increased Blood GlucoseLevels than in Individuals with Normal Levels. J Nucl Med Radiat Ther 2014; 5:167.
49. Brock KE, et al. Vitamin D and Metabolic Syndrome in Immigrant East Asian Women Living in Sydney,Australia: A Pilot. J Metabolic Synd 2012; 1:103.
50. Takeda M, et al. The Cleaning Effect of Shampooing Care by Adenosine Triphosphate BioluminescenceSystem. J Nurs Care 2012; S2:001.
51. Sachinkumar Patil et al. Antidiabetic drug loaded biodegradable nanoparticles for the management ofDiabetes mellitus. Pharmaceut Anal Acta 2013; 4:2.
52. Ashish Jain and Sanjay K Jain. L-valin conjugated PLGA nanoparticles for oral insulin delivery.Pharmaceut Anal Acta 2014; 5:3.
53. Shpakov AO et al. The Brain Adenylyl Cyclase Signaling System and Cognitive Functions in Rats withNeonatal Diabetes under the Influence of Intranasal Serotonin. J Metabolic Synd 2012; 1:104.
54. Berumen LC and García AG. 5-Ht5a Receptors during Ontogeny. J Genet Syndr Gene Ther 2014; 5:e126.
55. del Castillo N et al. 759C/T Variants of the Serotonin (5-HT2C) Receptor Gene and Weight Gain inChildren and Adolescents in Long-Term Risperidone Treatment. Clin Pharmacol Biopharm 2:110.
56. Watry S and Lu. JA Brief Summary for 5-HT Receptors. J Genet Syndr Gene Ther 2013; 4:129.
57. Lu J. Transgenic Animal Models for Brain 5-HT Deficiency: An Editorial Summary. J Genet Syndr GeneTher 2013; 4:e121.
58. Enrique Hong Chong. Antihiperglycemic effect of 5-HT2 receptor stimulation induced by a serotoninanalogue. J Diabetes Metab 2014; 5:10.
59. Kenneth A Chinkwo et al. Can interference of GIP activity modulate GPCRs for therapeutic gains?. ClinicPharmacol Biopharmaceut 2013; 2:3.
60. Utoh-Nedosa Uchechukwu Anastasia. “Nicotinic” receptors are 5-hydroxytryptamine receptors: Evidencefrom relaxation effect of d-tubocurarine and hexamethonium on chick rectum smooth muscles. ClinicPharmacol Biopharmaceut 2013; 2:3.
61. Helena Sarac et al. Platelet serotonin level and polymorphisms of serotonin transporter gene in patientswith Sjogren's syndrome: Association with depression and fatigue. J Clin Cell Immunol 2013; 4:5.
62. Clarina I. N’Da et al. The inhibition of acetylcholinesterase by dantrolene and ondansetron. Med chem2013; 3:4.
63. Rapolu Bharath Kumar et al. Formulation and evaluation of oral disintegrating tablets of sumatriptansuccinate. Pharmaceut Reg Affairs 2012; 1:4.
64. Ronan Bureau. Pharmacophores vs Emerging fragments: Implications in the comprehension ofpolypharmacological and toxicological properties of chemical derivatives. Drug Design 2012; 1:2.
65. Wei-Chiang Shen. Recombinant proinsulin-transferrin fusion protein as an insulin prodrug for thetargeted inhibition of hepatic glucose production. Pharmaceut Anal Acta 2013; 4:2.
66. Neelesh Kumar Mehra and N K Jain. Development and characterization of targeting ligand decoratedmulti-walled carbon nanotubes for targeting potential to cancer cells. Pharmaceut Anal Acta 2014; 5:3.
67. Sharif. Antibody conjugated nanoparticles encapsulating a photosensitizer: A photodynamic therapeuticstrategy. Pharmaceut Anal Acta 2014; 5:3.
68. Mansi K Shah and Senshang Lin. Preparation, in vitro evaluation, statistical optimization and in vitroabsorption mechanism of carvedilolloaded solid lipid nanoparticles for oral delivery. Pharm Anal Acta2015; 6:1.
69. Eric Cox. Targeting aminopeptidase N on enterocytes rapidly induces an IgA response in a pig model. JVaccines Vaccin 2014; 5:5.
70. Kate VK et al. Sodium alginate based new bioadhesive and rapid oromucosal absorptive sublingualtablet system for intraoral drug delivery. J Nanomedic Nanotechnol 2012; 3:1.
71. Chaudhary M et al. Overcoming Pseudomonas aeruginosa Resistance Caused by Glycocalyx withTobracef. J Microb Biochem Technol 2014; 6:207-211.
72. Alexander V Maksimenko. The conjugation of superoxide dismutase with catalase via chondroitinsulphate for targeting protection of vascular wall. Pharmaceut Anal Acta 2014; 5:3.
73. Alexander V Maksimenko and Robert S Beabealashvili. Stratification of surface lysine residues of bovinetesticular hyaluronidase on the basis of its 3D structure model: Design of chondroitin sulphate modifiedenzyme derivative. Pharmaceut Anal Acta 2014; 5:3.
74. Alexander V Maksimenko. Conjugated glycoenzymes for targeted and prophylaxy action against vascularinjuries. Biochem Anal Biochem 2013; 2:4.
75. Alexander V Maksimenko. Endothelial glycocalyx of microcirculation is the custodian of vascularintegrality in acute injuries. Biochem Anal Biochem 2013; 2:4.
76. Alexander V. Maksimenko and Robert S. Beabealashvili. Stratification of surface lysine residues of bovinetesticular hyaluronidase on the base of its 3D structure model: Computer aided drug designing ofchondroitin sulphate modified enzyme derivative. Med chem 2013; 3:4.
77. Dasan MK. Preclinical testing of experimental second brain drug delivery system for treating cancer:Abridged study. J Cancer Sci Ther 2014; 6:10.
78. Gulam Mustafa et al. Modified surface coated nanoemulsion bearing ropinirole to target brain for thebetter management of Parkinsonism: A scintigraphic evaluation. J Nanomedic Nanotechnol 3:1.
79. Su Chen. Marine Phospholipids Based Potential Brain Drugs. Pharm Anal Acta 2012; 3:1.
80. Jiukuan Hao. Application of nanotechnology for targeting brain delivery. J Bioequiv Availab 2013; 5:3.
81. Sancini G. Functionalization with TAT-Peptide Enhances Blood-Brain Barrier Crossing In vitro ofNanoliposomes Carrying a Curcumin-Derivative to Bind Amyloid-Β Peptide. J Nanomed Nanotechol 2013;4: 171.
82. Gosselet F. The Mysterious Link between Cholesterol and Alzheimer's Disease: Is the Blood-Brain Barriera Suspect? J Alzheimers Dis 2011; 1:103e.
83. Prasad S, et al. Diabetes Mellitus and Blood-Brain Barrier Dysfunction: An Overview. J Pharmacovigilance2:125.
84. Burek M, et al. Differential Cytokine Release from Brain Microvascular Endothelial Cells Treated withDexamethasone and Multiple Sclerosis Patient Sera. J Steroids Hormon Sci 2014; 5:128.
85. Maria Jose MB et al. Mentholated Cigarettes are Related With Abnormal Brain-Derived NeurotrophicFactor Levels among Smokers Living with HIV. J Alcohol Drug Depend 2014; 2:180.
86. Schober ME et al. Isoflurane Exposure did not Adversely Affect Recognition Memory or DecreaseHippocampal Brain Derived Neurotrophic Factor Expression in the 17 Day Old Rat Pup. J Anesth Clin Res2013; 4:362.
87. Shu Q et al. Is Brain-derived Neurotrophic Factor a Possible Mechanism Underlying RisperidoneSensitization in Adolescent Rats?. Biochem Pharmacol (Los Angel) 2013; S1:004.
88. Wang H et al. Chiari I Malformation with Acute Brain Stem Compression Syndromes Requiring EmergencyNeurosurgical Intervention: Report of Two Cases. J Neurol Disord 2014; 2: 177.
89. Saracoglu KT. Patient Safety and Preoperative Assessment of Neurological Status in NeurosurgicalPatients. Surgery Curr Res 2014; 4:e114.
90. Qiu L. Rational Design of Synthetic Polymers as Drug Carriers for Cancer Therapy. J Mol Pharm OrgProcess Res 1:e101.
91. Nazik A Elgindy. Protein-based nano-carriers as promising drug and gene delivery systems. PharmaceutAnal Acta 2013; 4:2.
92. Pushpendra K Tripathi. Haematotoxicological evaluation of dendrimeric nanoformulation of doxorubicin. JClinic Toxicol 2013; 3:5.
93. Mukesh Sharma et al. Hydrotalcite as a potential drug delivery vehicle for NSAIDS. Pharmaceut Anal Acta2013; 4:2.
94. Filippo Caraci. Rescue of TGF-b1 signalling as a new strategy for neuroprotection in AD: Role ofantidepressant drugs. J Alzheimers Dis Parkinsonism 2014; 4:5.
95. R Suresh Kumar. E-Pharmaceutica- lipid digestion media (lipolysis) an effective tool for the prediction offate of the drug in gastrointestinal tract from lipid based drug delivery system. Pharm Anal Acta 2015;6:1.
96. Robert Pola et al. Polymer drug carriers with enhanced penetration into tumor cells. Pharm Anal Acta2015; 6:1.
97. Nehoff H et al. The Influence of Drug Loading on Caveolin-1 Mediated Intracellular Internalization ofDoxorubicin Nanomicelles in vitro. J Nanomed Nanotechnol 2014; 5:197.
98. Al-Achi A and Jonathan Lawrence BS. Micelles: Chemotherapeutic Drug Delivery. Clin PharmacolBiopharm 2013; 2:e114.
99. Khan DR. The Use of Nanocarriers for Drug Delivery in Cancer Therapy. J Cancer Sci Ther 2010; 2: 058-062.
100. Suryakanta Swain et al. Supramolecular biovectors: Novel nanopolymers for drug delivery andgene therapy. Pharmaceut Reg Affairs 2012; 1:4.
101. C Vijaya Raghavan et al. Development of polysorbate-80 coated galantamine nanorticles to treatAlzheimer’s disease. J Alzheimers Dis Parkinsonism 2014; 4:5.
102. Hari S Sharma et al. Nanodrug delivery of a multimodal novel drug cerebrolysin reducesengineered nanoparticles induced aggravation ofheat stroke induced ubiquitin expression and brain pathology. J Nanomed Nanotechnol 2014; 5:5.
103. Edward P C Lai and Samar Alsudir. Polymer coatings for sensitive analysis of colloidalnanoparticles in water. J Anal Bioanal Tech 2014; 5:4.
104. Anjali singh et al. Resveratrol nanoparticles improve oral delivery and arrests the progression ofParacetamol-induced liver cirrhosis: Stability assessment, In-vitro and In-vivo studies. Pharmaceut Anal Acta 2013; 4:2.
105. Pankaj Sharma. A review of advances in injectable drugs and devices. Pharm Anal Acta 2015;6:1.
106. G.E.Zaikov. Biodegradation and Medical Application of Microbial poly(3- hydroxybutyrate). PharmAnal Acta 2012; 3:1.
107. Zaikov GE, et al. Biodeterioration and application of microbial poly (3-hydroxybutyrate). J BioanalBiomed 2013; 5:4
108. Xin H. Double Chimeric Peptide Vaccine and Monoclonal Antibodies that Protect AgainstDisseminated Candidiasis. J Vaccines Vaccin 2014; 5:241.
109. Dasan MK. Preclinical testing of experimental second brain drug delivery system for treatingcancer: Abridged study. J Cancer Sci Ther 2014; 6:10.
110. Su Chen. Marine Phospholipids Based Potential Brain Drugs. Pharm Anal Acta 2012; 3:1.
111. Santos-Oliveira R and Fleming B. Are Radiopharmaceuticals Safe? The Case of FDG-18. AdvPharmacoepidem Drug Safety 2012; 1:102.
112. Santos-Oliveira R. Pharmaceutical Equivalence and Bioequivalence of Radiopharmaceuticals:Thinking the Possibility of Generic Radiopharmaceuticals and Preparing for New Technology as Nanotechnology Drugs. J Bioequiv Availab 2014; 6:023-023.
113. Giulio Maria Pasinetti. Anti-hypertensive drugs for the treatment of Alzheimer’s disease. J NeurolNeurophysiol 2012; 3:6.
114. Haar CV et al. The Use of Nicotinamide as a Treatment for Experimental Traumatic Brain Injuryand Stroke: A Review and Evaluation. Clin Pharmacol Biopharm 2013; S1:005.
115. Lapchak PA et al. Synergistic Effect of AJW200, a von Willebrand Factor Neutralizing Antibodywith Low Dose (0.9 mg/mg) Thrombolytic Therapy Following Embolic Stroke in Rabbits. J Neurol Neurophysiol 4:146.
116. Yu CG. RNAi Approaches for Neuroprotection and Regeneration after Brain and Spinal Cord Injury.J Spine 2013; S4:e001.
117. Gavasane AJ, Pawar HA. Synthetic Biodegradable Polymers Used in Controlled Drug DeliverySystem: An Overview. Clin Pharmacol Biopharm 2014; 3:121.
118. Kamran Atif. Microencapsulation-Effective drug delivery system. Pharmaceut Anal Acta 2014;5:3.
119. Ipsita Roy. Biomaterials for tissue engineering. J Tissue Sci Eng 2014; 5:3.
120. M Vani and Giri Rajsekhar. Drug release kinetics in polymeric delivery systems. J Bioanal Biomed2014; 6:2.